Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
Authors:
- Yi-Long WuYWYi-Long Wu
- Nagahiro SaijoNSNagahiro Saijo
- Sumitra ThongprasertSTSumitra Thongprasert
- J. C.-H. YangJYJ. C.-H. Yang
- Baohui HanBHBaohui Han
- Benjamin MargonoBMBenjamin Margono
- Busayamas ChewaskulyongBusayamas Chewaskulyong
- Patrapim SunpaweravongPSPatrapim Sunpaweravong
- Yuichiro OheYOYuichiro Ohe
- Yukito IchinoseYIYukito Ichinose
- Jin-Ji YangJYJin-Ji Yang
- Tony S.K. MokTMTony S.K. Mok
Open Access
- 1 February 2017
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 104, 119-125
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca. IRESSA
This publication has 15 references indexed in Scilit:
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)Journal of Thoracic Oncology, 2014
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS studyLung Cancer, 2013
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)Annals of Oncology, 2013
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?Journal of Clinical Oncology, 2008
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)Nucleic Acids Research, 1989